Skip to main content
Terug
Watch Compare

ROCKWELL MEDICAL, INC.

Datakwaliteit: 83%
RMTI
Nasdaq Manufacturing Chemicals
€ 0,91
▼ € 0,02 (-2,15%)
Marktkapitalisatie: 37,20 M
Prijs
€ 0,94
Marktkapitalisatie
37,20 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Debt/Equity of 0,24 — conservative balance sheet
Negative free cash flow of -659.000,0

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-15,76%
Boven sectorgemiddelde (-53,34%)
ROIC-8,27%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,24
Onder sectorgemiddelde (0,31)
Current Ratio3,92
Interest Coverage-4,17

Waardering

PE (TTM)
-7,00
Onder sectorgemiddelde (-1,47)
P/B Ratio1,00
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -7,0 -1,5
P/B 1,0 1,6
ROE % -15,8 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,2 0,3

Koersdoel Analisten

2 analisten
Strong Buy
Huidig
€ 0,91
+229.7%
Koersdoel
€ 3,00
€ 2,00
€ 3,00
€ 4,00
Vooruitzicht
Forward WPA -€ 0,01
Omzet Sch. 79,99 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,01
-€ 0,06 – € 0,04
 79,99 M 2
FY2026 -€ 0,08
-€ 0,10 – -€ 0,05
 73,77 M 2

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 € 0,02 -€ 0,01 -150,0%
Q32025 -€ 0,05 -€ 0,05 -11,1%
Q22025 -€ 0,05 -€ 0,05 0,0%
Q12025 -€ 0,05 -€ 0,04 +20,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -5,31 M
ROE -15,76% ROA -9,65%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -659.000,0
ROIC -8,27% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,24 Current Ratio 3,92
Interest Coverage -4,17 Asset Turnover N/A
Working Capital 27,93 M Tangible Book Value 26,31 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7,00 Forward P/E N/A
P/B Ratio 1,00 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1,77%
Market Cap 37,20 M Enterprise Value 32,33 M
Per Share
EPS (Diluted TTM) -0,15 Revenue / Share N/A
FCF / Share -0,02 OCF / Share -0,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 12,40%
SBC-Adj. FCF -2,34 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -5,31 M -480.000,0 -8,44 M -18,68 M -32,67 M
EPS (Diluted) -0,15 -0,03 -0,37 -1,89 -0,35
Gross Profit 11,70 M 17,48 M 8,70 M 4,08 M -2,42 M
Operating Income -4,69 M 608.000,0 -6,67 M -16,78 M -30,34 M
EBITDA — — — — —
R&D Expenses 0,0 19.000,0 — — —
SG&A Expenses — — — — —
D&A 2,19 M 2,18 M 1,44 M 576.000,0 668.000,0
Interest Expense 1,12 M 1,25 M 2,30 M 1,94 M 2,36 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 57,15 M 59,21 M 52,17 M 46,64 M 48,57 M
Total Liabilities 20,16 M 26,62 M 30,88 M 32,53 M 46,04 M
Shareholders' Equity 36,98 M 32,59 M 21,29 M 14,11 M 2,54 M
Total Debt 8,83 M 8,47 M 8,29 M 7,56 M 13,19 M
Cash & Equivalents 10,71 M 15,66 M 8,98 M 10,10 M 13,28 M
Current Assets 38,16 M 37,03 M 28,77 M 35,31 M 35,29 M
Current Liabilities 9,58 M 14,09 M 16,64 M 17,69 M 20,97 M